Perimenopause is the standout leading indicator this week, posting an Emerging Demand Index score of 2.26 — nearly three times the next-highest condition. The driver is consumer attention: Wikipedia pageviews for perimenopause rose 32% week-over-week, a clean signal with no offsetting regulatory or trial noise. For Ob-Gyn and menopause-focused practices, this is the kind of upstream attention shift that typically precedes booking inquiries by 2–4 weeks.

Emerging Demand — What to Watch

  • Perimenopause (EDI 2.26) — Wikipedia pageviews +32% WoW, the strongest consumer-attention move on the board. No FDA or trials contribution; this is pure search-and-read behavior. Relevant for Ob-Gyn, menopause clinics, and women's health.
  • Wegovy (EDI 0.79) — Wikipedia pageviews +9% WoW. Steady reacceleration in the brand-specific GLP-1 read, with no new FDA action this week to explain it — suggesting organic consumer interest rather than news-driven spikes.
  • Mounjaro (EDI 0.73) — Wikipedia pageviews +8% WoW. Tracks closely with Wegovy, reinforcing that GLP-1 attention is broad rather than brand-specific this cycle.
  • Zepbound (EDI 0.60) — Wikipedia pageviews +6% WoW. The newest GLP-1 brand continues to compound attention more slowly than its established peers, but the trajectory is consistent.
  • Knee pain (EDI 0.54) — Wikipedia pageviews +5% WoW. A seasonal orthopedic signal as outdoor activity ramps; relevant for ortho and sports medicine capacity planning into late June.

Also notable below the top 5: anxiety (EDI 0.43) is driven not by consumer attention (Wikipedia -1% WoW) but by 19 new recruiting trials in the last 30 days — a supply-side signal worth watching for psychiatry and mental health operators tracking the trial-recruitment-to-referral pipeline.

Search Intent

Google Trends shows high blood pressure searches down 10%, with a recent 4-week average of 68 vs. 76 prior. That's a meaningful cooling in a high-volume primary care category and contradicts the structural BRFSS picture below — coincident search is softening even as prevalence remains elevated. No conditions registered as nationally rising in the IoT panel this week, which itself is a signal: demand attention is concentrating in the EDI categories (perimenopause, GLP-1s) rather than broad-based.

Structural Markets

Arkansas remains the most structurally underserved state on the board, with high blood pressure prevalence at 42.5% vs. 34% nationally (a +8.5 point gap), obesity at 38.9% vs. 34.3%, depression at 25.2% vs. 21.7%, and COPD at 9.6% vs. 6.3%. Four distinct chronic-care gaps in one state is a capacity-and-marketing opportunity for multi-specialty groups. The Rust Belt depression story also persists: Michigan at 26.7% and Ohio at 26.6% both run roughly 5 points above the 21.7% national rate — a durable tailwind for behavioral health expansion in those markets.

Respiratory Watch

Georgia is showing rising COVID activity, with 7 of 7 reporting HSAs trending up for the week ending May 30. Texas influenza is decisively past peak — 75 of 78 HSAs falling. Net: respiratory demand is local, not national, and Georgia operators should be the only ones adjusting staffing on this signal.

The Bottom Line

If you run an Ob-Gyn, menopause, or women's health line, this is the week to lean into perimenopause content and paid search — the attention curve is moving now and bookings will follow. GLP-1 demand is broad and steady across all four major brands, so brand-specific bidding matters less than category presence. Everyone else: ignore the noise, watch Arkansas and the Rust Belt for structural expansion, and let Georgia be the only place you touch your respiratory staffing plan.